News
StockStory.org on MSN1d
Hims & Hers Health’s Q1 Earnings Call: Our Top 5 Analyst QuestionsHims & Hers Health delivered a first quarter that surpassed Wall Street’s expectations, driven by strong adoption of its ...
2d
MarketBeat on MSNWhy Hims & Hers Is a Buy Below $35 After Its 16% PullbackThere is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
3don MSN
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
Hims & Hers' high valuation is no longer justified amid mounting execution and revenue risks. Click here to read why I ...
The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...
Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...
11don MSN
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results